The estimated Net Worth of Jonathan David Schwartz is at least $3.96 Million dollars as of 17 February 2023. Jonathan Schwartz owns over 3,557 units of Rocket Pharmaceuticals Inc stock worth over $1,799,210 and over the last 7 years he sold RCKT stock worth over $806,246. In addition, he makes $1,356,680 as Chief Medical Officer at Rocket Pharmaceuticals Inc.
Sign up
Jonathan Schwartz RCKT stock SEC Form 4 insiders trading
Jonathan has made over 3 trades of the Rocket Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 3,557 units of RCKT stock worth $67,796 on 17 February 2023.
The largest trade he's ever made was exercising 224,529 units of Rocket Pharmaceuticals Inc stock on 1 February 2021 worth over $276,171. On average, Jonathan trades about 19,506 units every 53 days since 2018. As of 17 February 2023 he still owns at least 94,546 units of Rocket Pharmaceuticals Inc stock.
You can see the complete history of Jonathan Schwartz stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jonathan Schwartz biography
Dr. Jonathan Schwartz M.D. serves as Chief Medical Officer of the Company. He joined us as Chief Medical Officer in January 2018 in connection with the Reverse Merger. Dr. Schwartz joined Private Rocket in January 2016 and served as Chief Medical Officer and Head of Clinical Development. Dr. Schwartz is responsible for leading our medical and program development. Dr. Schwartz has over 20 years of combined clinical practice and drug development experience. Prior to Private Rocket, Dr. Schwartz was Vice-President of Clinical Development at Stemline Therapeutics, where he oversaw development efforts for anticancer, vaccine and small-molecule platforms, a position he held since 2014. Prior to Stemline, he spent seven years at Eli Lilly and Company in several leadership positions, including Vice-President of Clinical Science, where he led development teams for numerous drug programs including ramucirumab. Previously, Dr. Schwartz was Associate Professor of Medicine at the Mount Sinai Medical Center in New York, specializing in the treatment and translational research of hepatobiliary malignancies and also served as Director for the Hematology-Oncology Fellowship training program. He has a BA in American Civilization from Brown University and an MD from Washington University (St. Louis). He completed post-graduate Internal Medicine and Hematology-Oncology training at the Mount Sinai and New York Presbyterian Hospitals.
What is the salary of Jonathan Schwartz?
As the Chief Medical Officer of Rocket Pharmaceuticals Inc, the total compensation of Jonathan Schwartz at Rocket Pharmaceuticals Inc is $1,356,680. There are 3 executives at Rocket Pharmaceuticals Inc getting paid more, with Gaurav Shah having the highest compensation of $3,883,650.
How old is Jonathan Schwartz?
Jonathan Schwartz is 56, he's been the Chief Medical Officer of Rocket Pharmaceuticals Inc since 2018. There are 4 older and 12 younger executives at Rocket Pharmaceuticals Inc. The oldest executive at Rocket Pharmaceuticals Inc is Pedro Granadillo, 73, who is the Independent Director.
What's Jonathan Schwartz's mailing address?
Jonathan's mailing address filed with the SEC is 228 STRAWBRIDGE DRIVE, SUITE 100, MOORESTOWN, NJ, 08057.
Insiders trading at Rocket Pharmaceuticals Inc
Over the last 7 years, insiders at Rocket Pharmaceuticals Inc have traded over $45,364,690 worth of Rocket Pharmaceuticals Inc stock and bought 2,407,332 units worth $48,979,646 . The most active insiders traders include Investments, Lpwong Roderic..., Mikael Dolsten und Investments, Lpwong Roderic.... On average, Rocket Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $1,269,815. The most recent stock trade was executed by John Militello on 16 August 2024, trading 1,064 units of RCKT stock currently worth $19,684.
What does Rocket Pharmaceuticals Inc do?
rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.
What does Rocket Pharmaceuticals Inc's logo look like?
Complete history of Jonathan Schwartz stock trades at Tabula Rasa HealthCare Inc und Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals Inc executives and stock owners
Rocket Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Gaurav Shah,
President, Chief Executive Officer, Director -
Kinnari Patel,
Chief Operating Officer and Head of Development -
Kamran Alam,
Senior Vice President - Finance, Principal Financial Officer -
Jonathan Schwartz,
Chief Medical Officer -
Dr. Gaurav D. Shah,
CEO & Director -
Kinnari Patel M.B.A., Pharm.D., PharmD, MBA,
Pres, COO & Head of Devel. -
Jonathan Schwartz,
Chief Medical Officer & Sr. VP of Clinical Devel. -
John C. Militello CPA, CPA,
VP, Sr. Controller & Principal Accounting Officer -
Roderick Wong,
Chairman of the Board -
Pedro Granadillo,
Independent Director -
Carsten Boess,
Independent Director -
Naveen Yalamanchi,
Independent Director -
Gotham Makker,
Independent Director -
David Southwell,
Director -
Elisabeth Bjork,
Independent Director -
John Militello,
Principal Accounting Officer and Senior Controller -
Dr. Gayatri R. Rao J.D., M.D.,
Chief Devel. Officer of LVV & Sr. VP -
Isabel Carmona J.D.,
Sr. VP & Chief HR Officer -
Kevin Giordano,
Director of Corp. Communications -
Martin L. Wilson,
Gen. Counsel, Chief Compliance Officer & Sr. VP -
Mayur Kasetty,
Bus. Devel. & Operations and Investor Relations Lead -
Carlos Garcia-Parada M.B.A.,
Chief Financial Officer -
Investments, Lpwong Roderic...,
-
Mark Andrew White,
See Remarks -
Investments, Lpwong Roderic...,
-
Roderickrtw Investments, Lp...,
-
Keith Woods,
-
Fady Ibraham Malik,
-
Carlos Garcia Parada,
Chief Financial Officer -
Martin Wilson,
General Counsel -
Mikael Dolsten,
-
Aaron Ondrey,
Chief Financial Officer